Embecta Corp. (EMBC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29082K1051
Embecta Corp. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.08 bn USD |
| Gross profit | 676.80 m USD |
| Operating income | 242.10 m USD |
| EBIT | 136.30 m USD |
| Net income | 95.40 m USD |
| Diluted EPS – continuing operations | 1.62 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Embecta Corp.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
More stocks
- JPP Holding Company Limited (5284.TW)
- USCB FINANCIAL HOLDINGS, INC. (USCB)
- HiVi Acoustics Technology Co Ltd (002888.SZ)
- Civeo Corp (CVEO)
- NATURAL GAS SERVICES GROUP INC (NGS)
- Lime Technologies AB (publ) (LIME.ST)
- Iperionx Ltd (IPX.AX)
- Jiangsu Tongda Power Technology Co Ltd (002576.SZ)
- PTG Energy PCL (PTG.BK)
- Shandong Shanda Oumasoft CO.LTD. (301185.SZ)
- Primis Financial Corp. (FRST)
- Teladan Prima Agro PT Tbk (TLDN.JK)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.